Eagle Pharmaceuticals Inc (OTCPK:EGRX)

$ 0.5 -0.0102 (-2%) Market Cap: 6.48 Mil Enterprise Value: - PE Ratio: 0 PB Ratio: 0 GF Score: 60/100

Eagle Pharmaceuticals Inc at Citi BioPharma Conference Transcript
Sep 07, 2023
Q2 2023 Eagle Pharmaceuticals Inc Earnings Call Transcript
Aug 08, 2023

$22.88 (+4.91%)

Earnings
Q1 2023 Eagle Pharmaceuticals Inc Earnings Call Transcript
May 09, 2023

$25.29 (-13.30%)

Earnings
Eagle Pharmaceuticals Inc at Barclays Global Healthcare Conference Transcript
Mar 15, 2023
Q4 2022 Eagle Pharmaceuticals Inc Earnings Call Transcript
Mar 13, 2023

$25.51 (+1.80%)

Earnings
Eagle Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript
Jan 10, 2023
Eagle Pharmaceuticals Inc Investor Day Transcript
Dec 06, 2022
Q3 2022 Eagle Pharmaceuticals Inc Earnings Call Transcript
Nov 07, 2022

$39.73 (+25.93%)

Earnings
Eagle Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 13, 2022
Q2 2022 Eagle Pharmaceuticals Inc Earnings Call Transcript
Aug 09, 2022

$36.86 (-14.46%)

Earnings
Q1 2022 Eagle Pharmaceuticals Inc Earnings Call Transcript
May 09, 2022

$42.95 (-0.69%)

Earnings
Eagle Pharmaceuticals Inc Corporate Call To Discuss BARHEMSYS®, BYFAVO® and Landiolol Opportunities Transcript
Mar 31, 2022
Q4 2021 Eagle Pharmaceuticals Inc Earnings Call Transcript
Mar 07, 2022

$47.75 (+5.88%)

Earnings
Eagle Pharmaceuticals Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 12, 2022
Q3 2021 Eagle Pharmaceuticals Inc Earnings Call Transcript
Nov 09, 2021

$51.4 (+0.61%)

Earnings
Eagle Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 14, 2021
Eagle Pharmaceuticals Inc Announces Worldwide Licensing Agreement with Combioxin SA Corporate Call Transcript
Sep 09, 2021
Q2 2021 Eagle Pharmaceuticals Inc Earnings Call Transcript
Aug 09, 2021

$47.84 (+4.52%)

Earnings
Q1 2021 Eagle Pharmaceuticals Inc Earnings Call Transcript
May 10, 2021

$38.47 (-7.64%)

Earnings
Q4 2020 Eagle Pharmaceuticals Inc Earnings Call Transcript
Mar 02, 2021

$40.4 (-10.97%)

Earnings
Eagle Pharmaceuticals Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 13, 2021
Q3 2020 Eagle Pharmaceuticals Inc Earnings Call Transcript
Nov 02, 2020

$49.22 (+5.80%)

Earnings
Eagle Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 14, 2020
Q2 2020 Eagle Pharmaceuticals Inc Earnings Call Transcript
Aug 10, 2020

$43.26 (-7.96%)

Earnings
Eagle Pharmaceuticals Inc Annual Shareholders Meeting Transcript
Jun 23, 2020
Q1 2020 Eagle Pharmaceuticals Inc Earnings Call Transcript
May 11, 2020

$54.57 (-0.82%)

Earnings
Q4 2019 Eagle Pharmaceuticals Inc Earnings Call Transcript
Mar 02, 2020

$41.86 (-8.80%)

Earnings
Eagle Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript
Jan 16, 2020
Q3 2019 Eagle Pharmaceuticals Inc Earnings Call Transcript
Nov 12, 2019

$58.34 (-5.61%)

Earnings
Eagle Pharmaceuticals Inc at Cantor Fitzgerald Global Healthcare Conference Transcript
Oct 02, 2019
Eagle Pharmaceuticals Inc at Morgan Stanley Healthcare Conference Transcript
Sep 11, 2019
Q2 2019 Eagle Pharmaceuticals Inc Earnings Call Transcript
Aug 08, 2019

$56.93 (+3.34%)

Earnings
Q1 2019 Eagle Pharmaceuticals Inc Earnings Call Transcript
May 07, 2019

$56.95 (+6.89%)

Earnings
Q4 2018 Eagle Pharmaceuticals Inc Earnings Call Transcript
Feb 28, 2019

$50.07 (+2.56%)

Earnings

Q4 2020 Eagle Pharmaceuticals Inc Earnings Call Transcript

Mar 02, 2021 / 01:30PM GMT

Release Date Price: $40.4 (-10.97%)

Transcript 10-K8-K

Operator

Good morning, everyone. My name is Leo, and I'll be your conference operator. At this time, I'd like to welcome everyone to Eagle Pharmaceuticals' Fourth Quarter and Full Year 2020 Financial Results and Pipeline Review Call. (Operator Instructions) As a reminder, this call -- conference call is being recorded today, March 2, 2021.

It is now my pleasure to turn the floor over to Ms. Lisa Wilson, Investor Relations for Eagle Pharmaceuticals. Please go ahead.

Lisa Wilson

Thank you, operator. Welcome to Eagle Pharmaceuticals' Fourth Quarter 2020 Earnings and Pipeline Review Call. This is Lisa Wilson, Investor Relations for Eagle Pharmaceuticals.

With me on today's call are Eagle's Chief Executive Officer, Scott Tarriff; Chief Financial Officer, Brian Cahill; President and Chief Operating Officer, David Pernock; and Chief Medical Officer, Dr. Judith Ng-Cashin.

This morning, the company issued a press release detailing financial results for the 3 months ended December 31, 2020. This press release and a webcast of this call can be accessed

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.